← Eichor
Study identifier: NCT07092670 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Condition: Melanoma · Fertility  ·  Sponsor: Intergruppo Melanoma Italiano

PhaseN/A
Planned participants270
Who can joinFemale, N/A to 40 Years
Healthy volunteersNo

About this study

Melanoma survivorship in reproductive-age women is increasing due to the advent of effective therapies in the curative setting. However, while the impact on fertility and ovarian function of chemotherapy agents is well known, there is still a lack of consistent data regarding novel the Mitogen-activated protein kinase (MAP) kinase pathway inhibitors and immune-checkpoint inhibitors (ICIs) used in melanoma. A recent study showed that a single course of anti-PD-1 (PD, Programmed cell death protein 1) or anti-CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) reduced both the number and quality of oocytes in mice through an immune-mediated mechanism. In particular, primordial follicle damage cannot be restored, leading to relevant clinical implications. The study aims to help to determine the impact of MAP kinase pathway inhibitors and ICIs on reproductive outcomes, and whether clinicians should discuss (and in what terms) fertility preservation techniques in reproductive-age women receiving ICIs and MAP kinase pathway inhibitors in the adjuvant setting.

This description comes directly from the study's public registry record.

Talk to the study team

Mario Mandalà  ·  0039 0755784211  ·  mario.mandala@unipg.it

Always discuss trial participation with your own doctor first.

Locations (10)

Ospedale Oncologico "Giovanni Paolo II"Bari, ItalyNot Yet Recruiting
IRCCS Ospedale Policlinico San Martino, Oncologia Medica 2Genova, ItalyNot Yet Recruiting
Fondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyNot Yet Recruiting
Azienda Ospedaliero-Universitaria, ModenaModena, ItalyNot Yet Recruiting
Istituto Nazionale Tumori "Fondazione Pascale"Naples, ItalyNot Yet Recruiting
IOV Istituto Oncologico VenetoPadova, ItalyNot Yet Recruiting
Azienda Ospedaliera Santa Maria della Misericordia - Unità di Oncologia Medica.Perugia, ItalyRecruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCSRoma, ItalyNot Yet Recruiting
Università degli Studi di Siena - U.O.C. Immunoterapia Oncologica Azienda Ospedaliera Universitaria SeneseSiena, ItalyNot Yet Recruiting
Università di Torino - Clinica DermatologicaTorino, ItalyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07092670